How is AI changing clinical trial design and patient stratification?

AI and machine learning — like NetraMark's explainable models — identify patient subgroups and surface signal in the small datasets typical of first-in-human and early-phase trials. bioaccess® pairs AI-informed design with fast, lower-cost Latin American execution and U.S. regulatory anchoring.

From the Global Trial Accelerators™ podcast with Dr. Joseph Geraci (NetraMark): watch the episode.

Where AI helps most in early-phase trials

Patient stratification and responder identification — finding subgroups that respond
Signal detection in small first-in-human datasets where classical statistics struggle
Explainable models that regulators and clinicians can interrogate (not black boxes)
Trial-design optimization: endpoints, enrichment, and sample-size efficiency
Caveat: AI is only as good as data quality and curation — garbage in, garbage out

Frequently asked questions

What is explainable AI in clinical trials?

Explainable AI refers to machine-learning models whose outputs can be interrogated and understood — not black boxes. In clinical trials this matters because regulators and clinicians must understand why a model identified a patient subgroup or predicted a response. Tools like NetraMark focus on explainability so AI-derived insights are defensible.

How does AI help small early-phase and first-in-human trials?

Early-phase and first-in-human trials have small sample sizes where traditional statistics are limited. AI can detect patterns, stratify patients, and find responder subgroups in that small data, helping sponsors learn more per patient — valuable when every patient is expensive and timelines matter.

Does AI replace biostatisticians in trial design?

No. AI augments — it surfaces hypotheses, stratifies patients, and optimizes design, but biostatistics, GCP rigor, and regulatory strategy remain essential. bioaccess® uses AI-informed design alongside conventional statistical and regulatory expertise.